Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 543 participants.

Also called NCT02762578

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 543 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02762578
  • EudraCT 2011-000085-36
Other papers using this trial's data
  • Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open-label, 2:1 randomized, treat-to-target trial Diabetes, obesity & metabolism, 2019-07 DOI, PubMed 30869183, PMC6617768 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02762578. Randomized; no masking; primary purpose treatment. Start 2016-05-03 (actual); primary completion 2017-05-19 (actual). Results posted on 2018-12-07.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes
Acronym
BOOST
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
insulin degludec/insulin aspart
Intervention (Drug)
biphasic insulin aspart
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct02762578
Content hash
52b2ee93dfa4152827f239e746f46ae371d23922e6ef66195f0b6472c86d860d